Cover Image
市場調查報告書

癌症免疫療法的全球市場的展望:2020年

Global Cancer Immunotherapy Market Outlook 2020

出版商 KuicK Research 商品編碼 332555
出版日期 內容資訊 英文 2600 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症免疫療法的全球市場的展望:2020年 Global Cancer Immunotherapy Market Outlook 2020
出版日期: 2015年06月01日 內容資訊: 英文 2600 Pages
簡介

本報告提供全球癌症免疫療法的市場相關調查、癌症免疫療法的分類、各癌症免疫療法概要及機制、各企業、適應症、階段的臨床實驗平台、已上市藥物的臨床性分析、市場的影響因素、市場現狀與未來展望,以及主要企業的簡介等彙整。

第1章 簡介:癌症免疫療法

第2章 癌症免疫療法的分類

第3章 癌症免疫療法:疫苗

  • 簡介
  • 癌症免疫療法的疫苗機制

第4章 癌症免疫療法:單株抗體

  • 簡介
  • 單株抗體的機制

第5章 癌症免疫療法:繼子細胞移植 (ACT:Adoptive Cell Transfer)

  • 簡介
  • ACT癌症免疫療法的機制

第6章 癌症免疫療法:免疫檢查站抑制劑

  • 簡介
  • 免疫檢查站抑制劑的機制

第7章 癌症免疫療法:免疫調製器

  • 簡介
  • 免疫調製器的機制

第8章 癌症免疫療法:細胞激素

  • 簡介
  • 細胞激素癌症免疫療法的機制

第9章 癌症免疫療法:白細胞介素

  • 簡介
  • 白細胞介素癌症免疫療法的機制

第10章 癌症免疫療法:干擾素

  • 簡介
  • 干擾素癌症免疫療法的機制

第11章 癌症免疫療法:GM-CSF

  • 簡介
  • GM-CSF癌症免疫療法的機制

第12章 癌症免疫療法市場概要

  • 目前市場方案
  • 癌症免疫療法的開發平台概要

第13章 全球癌症免疫療法市場動態

  • 有利的市場參數
  • 商業化的課題

第14章 全球癌症免疫療法市場:未來展望

第15章 癌症細胞療法的臨床實驗平台:各企業、適應症、階段

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段
  • 申請完畢

第16章 已上市癌症細胞治療藥的臨床性分析

  • Sipuleucel-T (ProvengeR)
  • T淋巴球細胞療法 (Immuncell-LCR)

第17章 癌症細胞激素的臨床實驗平台:各企業、適應症、階段

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段

第18章 已上市癌症細胞激素製劑的臨床性分析

  • Aldesleukin (Proleukin®)
  • Denileukin Diftitox (ONTAK®)
  • 干擾素α (Multiferon®)
  • 干擾素α-2a (Roferon-A®)
  • 干擾素α-2a (Veldona®)
  • 干擾素α-2a生技仿製藥(Inferon™/Inmutag™)
  • 干擾素α-2b(Intron® A)
  • 干擾素α-2b生技仿製藥(Bioferon™)
  • 干擾素α-2b生技仿製藥 (Intalfa®)
  • 干擾素α-2b生技仿製藥
  • 干擾素α-n3 (Alferon N®)
  • 干擾素β-1b (Feron®)
  • 干擾素伽馬 (Ogamma®)
  • 白細胞介素2生技仿製藥 (Ilcass)
  • Teceleukin (Imunace™)

第19章 癌症的免疫調製器的臨床實驗平台:各企業、適應症、階段

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段
  • 申請完畢
  • 已通過核准

第20章 已上市癌症免疫調製器的臨床性分析

第21章 癌症疫苗的臨床實驗平台:各企業、適應症、階段

  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段
  • 申請完畢
  • 已通過核准

第22章 已上市癌症疫苗的臨床性分析

  • 膀胱癌疫苗(PACISR)
  • 膀胱癌疫苗
  • BV NSCLC 001
  • 樹突狀細胞疫苗 (CreaVax-HCCR, CreaVax-PCR & CreaVax-RCCR)
  • 4價值人類乳突病毒疫苗 (GardasilR/SilgardR)
  • 組調換型2價值人類乳突病毒疫苗 (CervarixR)
  • 黑色素瘤疫苗 (MVaxR)
  • 黑色素瘤疫苗 (MelacineR)
  • Racotumomab (VaxiraR)
  • Sipuleucel-T (ProvengeR)
  • Tertomotide (LucaVax)
  • Vitespen (OncophageR)

第23章 癌細胞單克隆抗體的臨床實驗平台:各企業、適應症、階段

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段
  • 申請完畢
  • 已通過核准

第24章 已上市癌細胞單克隆抗體製劑的臨床性分析

第25章 競爭環境

  • Abbvie
  • Advaxis
  • Altor BioScience
  • Amgen
  • Biogen Idec
  • Biogenomics
  • Celldex Therapeutics
  • Dendreon Corporation
  • Eli Lilly
  • Expression Genetics
  • Galena Biopharma
  • Genmab
  • Gilead Sciences
  • GlaxoSmithKline
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Inovio Pharmaceuticals
  • IRX Therapeutics
  • Merck
  • NeoStem Oncology
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novartis
  • Peregrine Pharmaceuticals
  • Pfizer
  • Philogen
  • Regulon
  • Roche
  • Seattle Genetics
  • ZymoGenetics

圖表

目錄

Immune system is an intricate network of various tissues, organs and cell that prevents the attack by infectious agents. It prevents the growth and development of pathogens in body that may cause disease development. Wide array of potential disease causing microorganism like bacteria, fungus and virus are identified and eliminated in the body. Immune system also has ability to identify self from foreign cells due to which transplant rejection is observed. It has capability to generate memory that helps in providing long-term memory. Dead and abnormal cell are removed from the body that may hinder the normal functioning of cellular processes. It could also be trained to identify and eliminate particular cells from the body by giving suitable cues. Investigators have utilized this property of immune system to treat diseases by modulating immune responses. Investigators have extended this modality for preventing cancer progression and proliferation by stimulating patients' immune system.

Cancer immunotherapies have evolved significantly and numerous products have been introduced in the market. Many cancer immunotherapies are being tested in clinical trials for identification of their pharmacological and commercialization potential. Novel cancer immunotherapies are at different stages of clinical trials which would be introduced in coming years in global market. They could be broadly divided in two classes: specific and non-specific cancer immunotherapy. Basis of this classification is their ability to identify specific antigen related to particular malignancy. Modality used for developing them may be different but all of them will involve the activation of immune system for elimination of cancer. In some cases, overlapping boundaries may be found which is quite possible because single cancer immunotherapy may have multiple effects.

Cancer immunotherapeutics segment seems to be quite dynamic as it has received highly developed products which are absent in other cancer therapeutic category. This category has large number of products belonging to different categories resulting in myriad choices for patients to choose suitable products according to their necessities. They have been able to create dominance in cancer market segment of pharmaceutical industry which is expected to be continued for several years. Some of the products belonging to cancer immunotherapy were introduced few decades ago, while others have received marketing approval in past few years.

Versatility of these cancer immunotherapies allow them to be administrated for different cancer indications due to which their market share is increasing. Different cancer immunotherapy products have different pharmacological profiles due to which some products shows more acceptance rates as compared to other cancer immunotherapies. However, they have superior pharmacological capabilities as compared to their conventional counterparts.

Cancer immunotherapies harbor targeted therapeutics for the treatment of some malignancies. They have been made to target few antigens putatively linked to the cancerous cells. As a result, they have been introduced for limited malignancies due which large unmet medical necessities are observed in this segment. This fact was recognized by pharmaceutical companies and they started to lay emphasis on identification of new biomarkers. Biomarker identification followed by their development is a complex process and requires lots of time. This issue was solved by using knowledge from bioinformatics and allied fields which has been able to save time, investments and precious resources. However, pharmacological and commercialization potential of cancer therapeutics based on novel biomarkers would be known by clinical data.

New modalities, biomarkers and underlying principles are expected to be introduced in global market in coming years. These changes are expected to be propelled by increased fundings and technological advancement in the field of cancer immunotherapeutics. This scenario shows that they are going to play an important role in the treatment of various malignancies. All these facts show that cancer immunotherapies are going to have an optimistic future.

Cancer Immunotherapies Included in Report:

Adoptive Cell Transfer , GM-CSF, Immune Checkpoint Inhibitors, Immunomodulators, Interleukins, Interferon, Monoclonal Antibodies, Vaccines.

"Global Cancer Immunotherapy Market Outlook 2020" Report Highlight:

  • Introduction & Classification of Cancer Immunotherapy
  • Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
  • Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
  • Global Cancer Immunotherapy Pipeline: 1834 Drugs
  • Marketed Cancer Immunotherapies: 113 Drugs
  • Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
  • Cancer Vaccines Pipeline: 312 Vaccines
  • Marketed Cancer mAb: 36 mAb
  • Marketed Cancer Vaccines: 12 Vaccines

Table of Contents

1. Introduction to Cancer Immunotherapy

2. Classification of Cancer Immunotherapy

  • 2.1. Specific Cancer Immunotherapy
  • 2.2. Non-Specific Cancer Immunotherapy

3. Cancer Immunotherapy by Vaccines

  • 3.1. Introduction
  • 3.2. Mechanism of Vaccines in Cancer Immunotherapy
    • 3.2.1. Idiotype Cancer Vaccine Mechanism
    • 3.2.2. Cellular Cancer Vaccines Mechanism
    • 3.2.3. Ganglioside Antigens based Cancer Vaccines Mechanism
    • 3.2.4. Peptide Cancer Vaccine Mechanism
    • 3.2.5. Tumor Host Interaction Cancer Vaccine Mechanism

4. Cancer Immunotherapy by Monoclonal Antibodies

  • 4.1. Introduction
  • 4.2. Mechanism of Monoclonal Antibodies in Cancer Immunotherapy

5. Cancer Immunotherapy by Adoptive Cell Transfer

  • 5.1. Introduction
  • 5.2. Mechanism of Adoptive Cell Transfer Cancer Immunotherapy

6. Cancer Immunotherapy by Immune Checkpoint Inhibitors

  • 6.1. Introduction
  • 6.2. Mechanism of Immune Checkpoint Inhibitors in Cancer Immunotherapy

7. Cancer Immunotherapy by Immunomodulators

  • 7.1. Introduction
  • 7.2. Mechanism of Immunomodulators in Cancer Immunotherapy

8. Cancer Immunotherapy by Cytokines

  • 8.1. Introduction
  • 8.2. Mechanism of Cytokines Cancer Immunotherapy

9. Cancer Immunotherapy by Interleukins

  • 9.1. Introduction
  • 9.2. Mechanism of Interleukinsin Cancer Immunotherapy

10. Cancer Immunotherapy by Interferon

  • 10.1. Introduction
  • 10.2. Mechanism of Interferon Cancer Immunotherapy

11. Cancer Immunotherapy by GM-CSF

  • 11.1. Introduction
  • 11.2. Mechanism of GM-CSF Cancer Immunotherapy

12. Cancer Immunotherapy Market Overview

  • 12.1. Current Market Scenario
  • 12.2. Cancer Immunotherapy Pipeline Overview

13. Global Cancer Immunotherapy Market Dynamics

  • 13.1. Favorable Market Parameters
  • 13.2. Commercialization Challenges

14. Global Cancer Immunotherapy Market Future Prospects

15. Cancer Cell Therapies Clinical Pipeline by Company, Indication & Phase

  • 15.1. Unknown
  • 15.2. Research
  • 15.3. Preclinical
  • 15.4. Clinical
  • 15.5. Phase-I
  • 15.6. Phase-I/II
  • 15.7. Phase-II
  • 15.8. Phase-III
  • 15.9. Preregistration

16. Marketed Cancer Cell Therapies Drugs Clinical Insight

  • 16.1. Sipuleucel-T (Provenge®)
  • 16.2. T-Lymphocyte Cell Therapy(Immuncell-LC®)

17. Cancer Cytokines Clinical Pipeline by Company, Indication & Phase

  • 17.1. Unknown
  • 17.2. Research
  • 17.3. Preclinical
  • 17.4. Clinical
  • 17.5. Phase-I
  • 17.6. Phase-I/II
  • 17.7. Phase-II
  • 17.8. Phase-III

18. Marketed Cancer Cytokines Drugs Clinical Insight

  • 18.1. Aldesleukin (Proleukin®)
  • 18.2. Denileukin Diftitox (ONTAK®)
  • 18.3. Interferon Alpha (Multiferon®)
  • 18.4. Interferon Alpha-2a (Roferon-A®)
  • 18.5. Interferon Alpha-2a (Veldona®)
  • 18.6. Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
  • 18.7. Interferon Alpha-2b(Intron® A)
  • 18.8. Interferon Alpha-2b Biosimilar(Bioferon™)
  • 18.9. Interferon Alpha-2b Biosimilar (Intalfa®)
  • 18.10. Interferon Alpha-2b Biosimilar
  • 18.11. Interferon-Alpha-n3 (Alferon N®)
  • 18.12. Interferon-Beta-1b (Feron®)
  • 18.13. Interferon-Gamma (Ogamma®)
  • 18.14. Interleukin-2 Biosimilar (Ilcass)
  • 18.15. Teceleukin (Imunace™)

19. Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase

  • 19.1. Unknown
  • 19.2. Research
  • 19.3. Preclinical
  • 19.4. Clinical
  • 19.5. Phase-I
  • 19.6. Phase-I/II
  • 19.7. Phase-II
  • 19.8. Phase-II/III
  • 19.9. Phase-III
  • 19.10. Preregistration
  • 19.11. Registered

20. Marketed Cancer Immunomodulators Clinical Insight

21. Cancer Vaccine Clinical Pipeline By Company, Indication & Phase

  • 21.1. Research
  • 21.2. Preclinical
  • 21.3. Clinical
  • 21.4. Phase-I
  • 21.5. Phase-I/II
  • 21.6. Phase-II
  • 21.7. Phase-II/III
  • 21.8. Phase-III
  • 21.9. Preregistration
  • 21.10. Registered

22. Marketed Cancer Vaccines Clinical Insight

  • 22.1. Bladder Cancer Vaccine (PACIS®)
  • 22.2. Bladder Cancer Vaccine
  • 22.3. BV NSCLC 001
  • 22.4. Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)
  • 22.5. Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)
  • 22.6. Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
  • 22.7. Melanoma Vaccine (MVax®)
  • 22.8. Melanoma Vaccine (Melacine®)
  • 22.9. Racotumomab (Vaxira®)
  • 22.10. Sipuleucel-T (Provenge®)
  • 22.11. Tertomotide (LucaVax)
  • 22.12. Vitespen (Oncophage®)

23. Cancer Monoclonal Antibodies Clinical Pipeline by Company, Indication & Phase

  • 23.1. Unknown
  • 23.2. Research
  • 23.3. Preclinical
  • 23.4. Clinical
  • 23.5. Phase-I
  • 23.6. Phase-I/II
  • 23.7. Phase-II
  • 23.8. Phase-II/III
  • 23.9. Phase-III
  • 23.10. Preregistration
  • 23.11. Registered

24. Marketed Cancer Monoclonal Antibodies Drugs Clinical Insight

25. Competitive Landscape

  • 25.1. Abbvie
  • 25.2. Advaxis
  • 25.3. Altor BioScience
  • 25.4. Amgen
  • 25.5. Biogen Idec
  • 25.6. Biogenomics
  • 25.7. Celldex Therapeutics
  • 25.8. Dendreon Corporation
  • 25.9. Eli Lilly
  • 25.10. Expression Genetics
  • 25.11. Galena Biopharma
  • 25.12. Genmab
  • 25.13. Gilead Sciences
  • 25.14. GlaxoSmithKline
  • 25.15. ImmunoCellular Therapeutics
  • 25.16. ImmunoGen
  • 25.17. Inovio Pharmaceuticals
  • 25.18. IRX Therapeutics
  • 25.19. Merck
  • 25.20. NeoStem Oncology
  • 25.21. NewLink Genetics
  • 25.22. Northwest Biotherapeutics
  • 25.23. Novartis
  • 25.24. Peregrine Pharmaceuticals
  • 25.25. Pfizer
  • 25.26. Philogen
  • 25.27. Regulon
  • 25.28. Roche
  • 25.29. Seattle Genetics
  • 25.30. ZymoGenetics

List of Figures

  • Figure 1-1: Functions of Immune System
  • Figure 1-2: Necessity of Cancer Immunotherapies
  • Figure 1-3: Benefits of Cancer Immunotherapies
  • Figure 2-1: Classification of Cancer Immunotherapies
  • Figure 2-2: Specific Cancer Immunotherapies
  • Figure 2-3: Non-Specific Cancer Immunotherapies
  • Figure 3-1: Categorization & Function of Cancer Vaccines
  • Figure 3-2: Classification of Different Types of Cancer vaccines
  • Figure 4-1: Development of Monoclonal Antibody
  • Figure 4-2: Principle of Monoclonal Antibodies for Cancer Immunotherapy
  • Figure 4-3:Type of Cancer Monoclonal Antibodies
  • Figure 4-4: Mechanism of Alemtuzumab
  • Figure 4-5: Mechanism of Ibritumomab Tiuxetan
  • Figure 4-6: Mechanism of Blinatumomab
  • Figure 5-1: Benefit of Adoptive Cell Transfer Immunotherapy
  • Figure 5-2: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
  • Figure 5-3: Tumor-Infiltrating Lymphocytes Adoptive Cell Transfer Cancer Immunotherapy
  • Figure 5-4: Mechanism of CAR Modified T-Cells
  • Figure 5-5: Genetically Engineered TCR for Cancer Immunotherapy
  • Figure 6-1: Benefits of Immune Checkpoint Inhibitors
  • Figure 6-2:Mechanism of Ipilimumab
  • Figure 6-3: Mechanism of Nivolumab
  • Figure 6-4:Mechanism of Pembrolizumab
  • Figure 7-1: Functions of Immunomodulators
  • Figure 7-2: Benefits of Immunomodulators
  • Figure 7-3: Limitations of Immunomodulators
  • Figure 7-4: Mechanism of Thalidomide
  • Figure 7-5: Mechanism of Lenalidomide In Vivo
  • Figure 7-6: Mechanism of Lenalidomide In Vitro
  • Figure 7-7: Mechanism of Pomalidomide
  • Figure 8-1: Functions of Cytokine
  • Figure 8-2: Benefits of Cytokine in Cancer Immunotherapy
  • Figure 9-1: Functions of Interleukin
  • Figure 9-2: Benefits of Interleukins in Cancer Immunotherapy
  • Figure 9-3: Mechanism of Proleukin
  • Figure 9-4: Mechanism of Denileukin Diftitox
  • Figure 10-1: Major Types of Cytokine
  • Figure 10-2: Functions of Interferon
  • Figure 10-3: Classification of Interferons on the Basis of Types of Genes
  • Figure 10-4: General Mechanism of Interferons
  • Figure 10-5: Mechanism of Interferon Alfa-n3
  • Figure 10-6:Mechanism ofPeginterferon Alfa-2a
  • Figure 10-7: Mechanism ofInterferon Beta 1a
  • Figure 10-8: Mechanism of Interferon Alfa-2b
  • Figure 11-1: Usage of GM-CSF
  • Figure 11-2: Mechanism of Sargramostim
  • Figure 12-1: Cancer Immunotherapy Pipeline by Phase (%), 2015
  • Figure 12-2: Cancer Immunotherapy Pipeline by Phase (Number), 2015
  • Figure 12-3: Cancer Cytokines Pipeline by Phase (%), 2015
  • Figure 12-4: Cancer Cytokines Pipeline by Phase (Number), 2015
  • Figure 12-5: Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
  • Figure 12-6: Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
  • Figure 12-7: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
  • Figure 12-8: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
  • Figure 12-9: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
  • Figure 12-10: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
  • Figure 12-11: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
  • Figure 12-12: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
  • Figure 12-13: Cancer Vaccine Pipeline by Phase (%), 2015
  • Figure 12-14: Cancer Vaccine Pipeline by Phase (Number), 2015
  • Figure 12-15: No Development Reported Cancer Vaccine Pipeline by Phase (%), 2015
  • Figure 12-16: No Development Reported Cancer Vaccine Pipeline by Phase (Number), 2015
  • Figure 12-17: Discontinued Cancer Vaccine Pipeline by Phase (%), 2015
  • Figure 12-18: Discontinued Cancer Vaccine Pipeline by Phase (Number), 2015
  • Figure 12-19: Suspended Cancer Vaccine Pipeline by Phase (%), 2015
  • Figure 12-20: Suspended Cancer Vaccine Pipeline by Phase (Number), 2015
  • Figure 12-21: Cancer Immunomodulators Pipeline by Phase (%), 2015
  • Figure 12-22: Cancer Immunomodulators Pipeline by Phase (Number), 2015
  • Figure 12-23: Cancer Cell Therapies Pipeline by Phase (%), 2015
  • Figure 12-24: Cancer Cell Therapies Pipeline by Phase (Number), 2015
  • Figure 12-25: Discontinued Cancer Cell Therapies Pipeline by Phase (%), 2015
  • Figure 12-26: Discontinued Cancer Cell Therapies Pipeline by Phase (Number), 2015
  • Figure 13 1: Favorable Cancer Immunotherapy Market Parameters
  • Figure 13 2: Cancer Immunotherapy Commercialization Challenges
  • Figure 25-1: Advaxis Clinical Pipeline
  • Figure 25-2: Celldex Therapeutics Clinical Pipeline
  • Figure 25-3: Expression Genetics Clinical Pipeline
  • Figure 25-4: Galena Biopharma Clinical Pipeline
  • Figure 25-5: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 25-6: ImmunoGen Clinical Pipeline
  • Figure 25-7: Inovio Pharmaceuticals Clinical Pipeline
  • Figure 25-8: NewLink Genetics Corporation Clinical Pipeline
  • Figure 25-9: Northwest Biotherapeutics Clinical Pipeline
  • Figure 25-10: Peregrine Pharmaceuticals Clinical Pipeline
  • Figure 25-11: Philogen Clinical Pipeline
  • Figure 25-12: Seattle Genetics Clinical Pipeline

List of Tables

  • Table 4-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy
  • Table 6-1: Some Important Checkpoint Inhibitors
  • Table 8-1: Few Important Immunocytokines under Clinical Development
  • Table 8-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies
  • Table 12-1: Few Commercially Important PD-1 Drugs
Back to Top